Search
![](/globalassets/media/images/type-of-image/content-wide-card-block/media-release-drk-pink.jpg)
News & Events
The Kids researchers awarded Raine Medical Research Foundation fundingCongratulations to three The Kids Research Institute Australia researchers, who have been awarded funding from the Raine Medical Research Foundation.
News & Events
New imaging equipment to boost children's cancer researchA cutting edge cancer imaging facility will help specialist children's cancer researchers at Perth's Telethon Institute for Child Health Research.
![](/globalassets/media/images/pagessections/people-profiles/m/elizabeth-milne.jpg)
Research
Childhood and parental diagnostic radiological procedures and risk of childhood brain tumorsWe found no evidence of positive associations between risk of childhood brain tumours overall and childhood or parental pre-pregnancy radiological procedures.
Research
The Childhood Leukemia International ConsortiumThe Childhood Leukemia International Consortium (CLIC) was established in 2007 to promote investigations of rarer exposures, gene-environment interactions...
Research
Parental smoking and risk of childhood brain tumorsChildhood brain tumors (CBT) are the leading cause of cancer death in children, yet their etiology remains largely unknown.
Research
Parental alcohol consumption and risk of childhood acute lymphoblastic leukemia and brain tumorsChildhood acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and brain tumors (CBTs) are the leading cause of cancer death in...
Research
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63We hypothesized that reactivation of p53 by inhibition of its negative regulator will result in p53-mediated growth arrest and apoptosis.
Research
MEIS proteins as partners of the TLX1/HOX11 oncoproteinAberrant expression of the TLX1/HOX11 proto-oncogene is associated with a significant subset of T-cell acute lymphoblastic leukemias...
Research
Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphomaIL7 and glucocorticoids coordinately drive aberrant activation of PIM1 and suggests that T-ALL and T-LBL patients could benefit from PIM inhibition